Specialty Drugs Market Size, Share & Industry Analysis, By Molecule Platform (Biologics, Specialty Small Molecules, Cell & Gene Therapies, Radiopharmaceuticals, and Others), By Disease Indication (Oncology, Autoimmune & Inflammatory Disorders, Rare Diseases/Orphan Disorders, Neurology, Hematology, Infectious Diseases, and Others), By Formulation (Oral and Parenteral {Intravenous (IV), Subcutaneous (SC), Intramuscular (IM), and Others}), By End User (Hospitals, Specialty Clinics & Infusion Centers, Home Care / Home Infusion, and Others), and Regional Forecast, 2026-2034

Last Updated: May 15, 2026 | Format: PDF | Report ID: FBI116144

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 7.08% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Molecule Platform, Disease Indication, Formulation, End User, and Region
By Molecule Platform	Biologics Specialty Small Molecules Cell & Gene Therapies Radiopharmaceuticals Others
By Disease Indication	Oncology Autoimmune & Inflammatory Disorders Rare Diseases/Orphan Disorders Neurology Hematology Infectious Diseases Others
By Formulation	Oral Parenteral Intravenous (IV) Subcutaneous (SC) Intramuscular (IM) Others
By End User	Hospitals Specialty Clinics & Infusion Centers Home Care/Home Infusion Others
By Region	North America (By Molecule Platform, Disease Indication, Formulation, End User, and Country) U.S. Canada Europe (By Molecule Platform, Disease Indication, Formulation, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Molecule Platform, Disease Indication, Formulation, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Molecule Platform, Disease Indication, Formulation, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Molecule Platform, Disease Indication, Formulation, End User, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa